Published in Lancet on August 31, 1968
Arthropathy of haemochromatosis. Clinical and radiological analysis of 63 patients with iron overload. Ann Rheum Dis (1970) 2.09
Liver biopsy in the diagnosis of cirrhosis. Gut (1970) 1.53
Hepatocellular carcinoma in primary haemochromatosis in the absence of cirrhosis. Gut (1988) 1.37
Hereditary spherocytosis, haemochromatosis, diabetes mellitus and chondrocalcinosis. Proc R Soc Med (1973) 0.93
Hepatic iron overload and hepatocellular carcinoma. Liver Cancer (2014) 0.92
Thalassaemia minor, iron overload, and hepatoma. Br Med J (1978) 0.92
MicroRNAs and liver cancer associated with iron overload: therapeutic targets unravelled. World J Gastroenterol (2013) 0.88
Iron and the liver. Gut (1974) 0.83
Patients with hereditary spherocytosis may have clinically significant iron overload when they are also heterozygous for hemochromatosis. Trans Am Clin Climatol Assoc (1985) 0.78
Hereditary (primary) haemochromatosis. BMJ (1990) 0.75
Iron overload. Postgrad Med J (1969) 0.75
Coinheritance of hereditary spherocytosis and reversibility of cirrhosis in a young female patient with hereditary hemochromatosis. Eur J Med Res (2009) 0.75
Transection of the oesophagus for bleeding oesophageal varices. Br J Surg (1973) 26.26
Decision aids for people facing health treatment or screening decisions. Cochrane Database Syst Rev (2003) 10.43
Decision aids for patients facing health treatment or screening decisions: systematic review. BMJ (1999) 9.70
Tissue antibodies in primary biliary cirrhosis, active chronic (lupoid) hepatitis, cryptogenic cirrhosis and other liver diseases and their clinical implications. Clin Exp Immunol (1966) 8.26
Classification of chronic hepatitis: diagnosis, grading and staging. Hepatology (1994) 7.89
Early indicators of prognosis in fulminant hepatic failure. Gastroenterology (1989) 7.43
The presentation and diagnosis of 100 patients with primary biliary cirrhosis. N Engl J Med (1973) 6.65
Cost analysis of early discharge after hip fracture. BMJ (1993) 6.64
Deaths from low dose paracetamol poisoning. BMJ (1998) 6.63
Anti-tuberculous therapy and acute liver failure. Lancet (1995) 6.27
Causes and outcomes of the acute chest syndrome in sickle cell disease. National Acute Chest Syndrome Study Group. N Engl J Med (2000) 6.07
A classification of chronic hepatitis. Lancet (1968) 6.07
Global trends in resistance to antituberculosis drugs. World Health Organization-International Union against Tuberculosis and Lung Disease Working Group on Anti-Tuberculosis Drug Resistance Surveillance. N Engl J Med (2001) 6.05
Cellular immunity and hepatitis-associated, Australia antigen liver disease. Lancet (1972) 5.17
Acute liver failure: redefining the syndromes. Lancet (1993) 4.99
Vulnerability genes or plasticity genes? Mol Psychiatry (2009) 4.96
Hepatitis C virus antibodies in chronic active hepatitis: pathogenetic factor or false-positive result? Lancet (1990) 4.57
Urinary D-glucaric-acid excretion as a test for hepatic enzyme induction in man. Lancet (1971) 4.49
Liver transplantation in man. I. Observations on technique and organization in five cases. Br Med J (1968) 4.38
Improved outcome of paracetamol-induced fulminant hepatic failure by late administration of acetylcysteine. Lancet (1990) 4.27
Long-term outcome of hepatitis C infection after liver transplantation. N Engl J Med (1996) 4.10
Primary sclerosing cholangitis: a review of its clinical features, cholangiography, and hepatic histology. Gut (1980) 4.09
Daily variation of particulate air pollution and poor cardiac autonomic control in the elderly. Environ Health Perspect (1999) 4.07
Cell-mediated immunity to a human liver-specific antigen in patients with active chronic hepatitis and primary biliary cirrhosis. Lancet (1972) 3.90
The role of virus-specific CD8(+) cells in liver damage and viral control during persistent hepatitis B virus infection. J Exp Med (2000) 3.78
Inadequate antibody response to hBAg or suppressor T-cell defect in development of active chronic hepatitis. Lancet (1974) 3.61
Screening for type 2 diabetes: literature review and economic modelling. Health Technol Assess (2007) 3.40
Structured patient education: the diabetes X-PERT Programme makes a difference. Diabet Med (2006) 3.36
Detection of antibodies directed against a liver-specific membrane lipoprotein in patients with acute and chronic active hepatitis. N Engl J Med (1978) 3.28
Plasma endothelin immunoreactivity in liver disease and the hepatorenal syndrome. N Engl J Med (1992) 3.24
The International Health Program: the fifteen-year experience with Yale University's Internal Medicine Residency Program. Am J Trop Med Hyg (1999) 3.23
Controlled prospective trial of corticosteroid therapy in active chronic hepatitis. Q J Med (1971) 3.23
NHLBI Family Heart Study: objectives and design. Am J Epidemiol (1996) 3.21
Lymphocyte cytotoxicity to isolated hepatocytes in chronic active hepatitis. Nature (1974) 3.17
Purification and characterization of human liver-specific membrane lipoprotein (LSP). Clin Exp Immunol (1977) 3.13
Phenylbutazone and isoniazid metabolism in patients with liver disease in relation to previous drug therapy. Lancet (1968) 3.10
Improved survival after orthotopic liver grafting. Br Med J (Clin Res Ed) (1981) 3.09
Specificity of T lymphocyte cytotoxicity to autologous hepatocytes in chronic hepatitis B virus infection: evidence that T cells are directed against HBV core antigen expressed on hepatocytes. J Immunol (1982) 3.09
Mutations that alter the ability of the Escherichia coli cyclic AMP receptor protein to activate transcription. Nucleic Acids Res (1990) 3.08
Presence of a newly described human DNA virus (TTV) in patients with liver disease. Lancet (1998) 3.06
Liver transplantation for malignant disease. Results in 93 consecutive patients. Ann Surg (1988) 3.04
Controlled trial of prednisone and azathioprine in active chronic hepatitis. Lancet (1973) 2.98
Use of partial cardiopulmonary bypass during the anhepatic phase of orthotopic liver grafting. Lancet (1979) 2.98
Intravenous acetylcysteine in paracetamol induced fulminant hepatic failure: a prospective controlled trial. BMJ (1991) 2.94
More donor organs for transplantation. Elective ventilation proposals. J R Coll Physicians Lond (1993) 2.91
A controlled trial of D-penicillamine therapy in primary biliary cirrhosis. Lancet (1977) 2.90
The epidemiology of testicular cancer in young adults. Am J Epidemiol (1980) 2.90
Multisystem involvement in chronic liver disease. Studies on the incidence and pathogenesis. Am J Med (1973) 2.88
Altered calcium metabolism in epileptic children on anticonvulsants. Br Med J (1971) 2.86
The arthropathy of idiopathic haemochromatosis. Q J Med (1968) 2.85
Hepatitis B virus infection in medical and health care personnel. Br Med J (Clin Res Ed) (1982) 2.85
The aetiology, presentation and natural history of extra-hepatic portal venous obstruction. Q J Med (1979) 2.84
Spread of acute type-B hepatitis in London. Lancet (1973) 2.82
Liver transplantation after paracetamol overdose. BMJ (1991) 2.81
New hepatitis C virus (HCV) genotyping system that allows for identification of HCV genotypes 1a, 1b, 2a, 2b, 3a, 3b, 4, 5a, and 6a. J Clin Microbiol (1997) 2.78
Liver disease and bile duct abnormalities in adults with cystic fibrosis. Lancet (1989) 2.76
Liver in Felty's syndrome. Br Med J (1970) 2.75
Hepatic damage and death from overdose of paracetamol. Lancet (1973) 2.70
Extrahepatic biliary atresia versus neonatal hepatitis. Review of 137 prospectively investigated infants. Arch Dis Child (1976) 2.67
Cyclosporin A in cadaveric organ transplantation. Br Med J (Clin Res Ed) (1981) 2.67
Measurement of liver-iron concentration in needle-biopsy specimens. Lancet (1971) 2.65
Arterial changes in the lungs in cirrhosis of the liver--lung spider nevi. N Engl J Med (1966) 2.65
Decision aids for people facing health treatment or screening decisions. Cochrane Database Syst Rev (2001) 2.65
Improvement by acetylcysteine of hemodynamics and oxygen transport in fulminant hepatic failure. N Engl J Med (1991) 2.65
Prolonged bile duct obstruction: a new experimental model for cirrhosis in the rat. Br J Exp Pathol (1984) 2.63
Direct ex vivo analysis of hepatitis B virus-specific CD8(+) T cells associated with the control of infection. Gastroenterology (1999) 2.62
Relationship of hepatitis-associated antigen (H.A.A.) to acute and chronic liver injury. Lancet (1971) 2.61
Controlled trials of charcoal hemoperfusion and prognostic factors in fulminant hepatic failure. Gastroenterology (1988) 2.60
Hepatitis C virus genotypes: an investigation of type-specific differences in geographic origin and disease. Hepatology (1994) 2.60
Chronic liver disease and primary liver-cell cancer with hepatitis-associated (Australia) antigen in serum. Lancet (1970) 2.60
Treatment of hepatic encephalopathy. N Engl J Med (1997) 2.60
Serum ferritin in patients with iron overload and with acute and chronic liver diseases. Gastroenterology (1975) 2.58
Liver transplantation. Curr Probl Surg (1979) 2.57
Treatment of fulminant hepatic failure by polyacrylonitrile-membrane haemodialysis. Lancet (1977) 2.53
Acute liver failure secondary to hepatic infiltration: a single centre experience of 18 cases. Gut (1998) 2.51
Orthotopic liver transplantation: the first 60 patients. Br Med J (1977) 2.50
A habitable fluvio-lacustrine environment at Yellowknife Bay, Gale crater, Mars. Science (2013) 2.50
Electrical control of antiferromagnetic domains in multiferroic BiFeO3 films at room temperature. Nat Mater (2006) 2.49
The systemic inflammatory response syndrome in acute liver failure. Hepatology (2000) 2.47
RasGRP links T-cell receptor signaling to Ras. Blood (2000) 2.46
Determining cause of death in prostate cancer: are death certificates valid? J Natl Cancer Inst (2001) 2.46
Partial nodular transformation of the liver with portal hypertension. Am J Med (1966) 2.45
Incubation phase of acute hepatitis B in man: dynamic of cellular immune mechanisms. Hepatology (2000) 2.45
Attentional bias in anxiety and depression: the role of awareness. Br J Clin Psychol (1995) 2.43
Developing and deploying a patient safety program in a large health care delivery system: you can't fix what you don't know about. Jt Comm J Qual Improv (2001) 2.42
Azathioprine for long-term maintenance of remission in autoimmune hepatitis. N Engl J Med (1995) 2.41
Antibodies to the surface of halothane-altered rabbit hepatocytes in patients with severe halothane-associated hepatitis. N Engl J Med (1980) 2.41
1 -Antitrypsin deficiency and neonatal hepatitis. Br Med J (1972) 2.40
Cell-mediated immunity in patients positive for hepatitis-associated antigen. Br Med J (1972) 2.39
General practice orthopaedic outpatient referrals in North Staffordshire. Br Med J (Clin Res Ed) (1983) 2.38
Relation of renal impairment and haemorrhagic diathesis to endotoxaemia in fulminant hepatic failure. Lancet (1974) 2.37
Draft guidance for industry extended-release solid oral dosage forms. Development, evaluation and application of in vitro-in vivo correlations. Adv Exp Med Biol (1997) 2.35